Opinion
Video
Less Common Molecular Alterations in pLGG and Testing Recommendations
Author(s):
The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for patient care.
EP: 1.Overview of pLGG presentation and categorization
EP: 2.Molecular Characterization of pLGG
Now Viewing
EP: 3.Less Common Molecular Alterations in pLGG and Testing Recommendations
EP: 4.Standard of care for frontline treatment of non-V600E-specific pLGG tumors
EP: 5.Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors
EP: 6.Current Treatment of Patients with NF1 pLGG
EP: 7.Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG
EP: 8.Treatment Considerations for Progressive pLGG
EP: 9.Radiation and Targeted Therapies for Progressive pLGG
EP: 10.The Role of Tovorafenib in Treatment of Progressive pLGG
EP: 11.Clinical Trials to Increase Treatment Options in the Progressive Setting
EP: 12.Clinical scenario 1 - BRAFKIAA-1549 fusion
EP: 13.Alternatives and Considerations for Clinical Scenario 1
EP: 14.Clinical Scenario 2 - BRAFV600E
EP: 15.Potential Adverse Events With Targeted Therapies
EP: 16.Clinical Insights: Looking Forward for pLGG
- Are there particular considerations depending on the type of BRAF alteration?
Related Videos
Related Content
